AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04709887 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tibial transverse transport surgery
Description: In the anteromedial area of the proximal tibia of the affected limb, the external fixation frame was compared with the area along the midline of the medial longitudinal axis of the proximal tibia. Subsequently, two 3.0 Steinmann pins were inserted through the single layer of cortical bone. The skin was cut along the long axis with the 3.0 Steinmann pin as the centre, and the subcutaneous tissue was separate bluntly to expose the periosteum. The Steinmann pins were used as the centre point for the drilling on four sides with a 2.0 drill bit and use of a rapid osteotomy device; the length of each side was 2.5 cm. Subperiosteal osteotomy was performed with a 5-mm narrow bone knife at an angle of 15°-30° to the bone surface. The surgeons should pay attention to protect the blood supply of the periosteum during this procedure. The external fixators were fixed with 4.0 Steinmann pins at the distal and proximal ends. The subcutaneous tissue and skin were sutured.
Study NCT00714571 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mnemonic strategy training (MST)
Study NCT00714571 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Repeated exposure (XP)
Study NCT00714571 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Subtracting Cues training
Study NCT04514354 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GEST
Description: On either Visit 3 or 4, subjects performed a maximal cardiopulmonary GEST following the Balke protocol. Immediately prior to the GEST, the study physician or his designee performed a brief physical examination, in which BP was assessed and all relevant medical information (i.e. medical history, medications, family history) were reviewed. The physician who completed the physical examination remained present during the GEST to monitor the subjects' electrocardiogram (ECG) and other physical signs. After the GEST was completed, the study physician reviewed the ECG for signs of ischemia. Breath-by-breath analysis of expired gases (i.e. oxygen and carbon dioxide) (ParvoMedicsTruneOne® 2400 Metabolic Measurement System, ParvoMedics Inc., Sandy, UT) determined maximal oxygen uptake (VO2max). Heart rate was measured continuously with a 12-lead ECG system and BP was measured by auscultation every 3 minutes during the GEST.
Study NCT01210417 — intervention group
Intervention type: OTHER
Intervention: Non invasive monitoring
Description: Three-lead electrocardiogram (ECG), PPG oxymetry, non-invasive blood pressure (NIBP) are registered
Study NCT01693172 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early mobilization program
Description: Early postoperative supervised aerobic exercise, resistance and flexibility training
Study NCT00819741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: repaglinide
Description: The dose was started from repaglinide 1 mg three times daily. During the dose titration period, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose.
Study NCT02419937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: 162 mg subcutaneously once (vs. 0.9% normal saline placebo injection once in placebo arm)
Study NCT02419937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline injection
Study NCT03389438 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous Tcm cells immunotherapy
Description: Autologous Tcm cells immunotherapy is to collect patient's own immune cells and infuse back into the patient's body after culture in vitro that can activate the anti-tumor immune response and achieve the purpose of cancer treatment.
Study NCT00693966 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 1)
Description: IM injection
Study NCT00693966 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 2)
Description: IM injection
Study NCT00693966 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 3)
Description: IM injection
Study NCT00693966 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-517 HPV-16/18 VLP with Al(OH)3 (Formulation 4)
Description: IM injection
Study NCT04444557 — intervention group
Intervention type: OTHER
Intervention: Beck Depression Inventory (BDI)
Description: The Beck Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression
Study NCT04074174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0174-0833
Description: NNC0174-0833 administered s.c. (subcutaneously, under the skin) once weekly for 12 weeks
Study NCT04074174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC) tablets
Description: 1 tablet daily on days 1-8 and days 79-86
Study NCT04074174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Single dose of acetaminophen as part of a standardised meal on day 1 and day 79
Study NCT04373278 — intervention group
Intervention type: OTHER
Intervention: failure of reconstruction of the mandibule by free fibula flap
Description: description of failure of reconstruction of the mandibule by free fibula flap:delay, type of bacteria involved in the failure, treatment, outcome
Study NCT04177368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Theragran 60ml
Description: history,examination and biochemical values
Study NCT00828035 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparoscopic surgery
Description: comparison of two different laparoscopic surgeries : robot versus human
Study NCT00828035 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic surgery
Description: comparison of two different laparoscopic surgeries : robot versus human
Study NCT00894283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Patients will receive enoxaparin 40mg subcutaneously twice daily during perioperative period of bariatric surgery. Patients will be encouraged to ambulate and compression stockings while in bed.
Study NCT00894283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fondaparinux
Description: Fondaparinux 5mg subcutaneously 6 hours following surgery, fondaparinux 5mg subcutaneously once daily during hospitalization. Patients will be encouraged to ambulate and compression stockings while in bed.
Study NCT00147030 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Whole body mild induced hypothermia
Description: Target rectal temperature 33-34°C for 72 hours, commencing by 6 hours of age; followed by re-warming at 0.5°C to normothermia
Study NCT01303848 — intervention group
Intervention type: OTHER
Intervention: Blood Sampling
Description: Blood Sampling over 24 hours
Study NCT03867994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Study NCT03867994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Study NCT03867994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saline
Study NCT01183585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838 and Rosuvastatin
Description: multiple oral doses of RO4917838 and single oral dose of Rosuvastatin
Study NCT01346397 — intervention group
Intervention type: DRUG
Intervention: cyclosporine or tacrolimus
Description: after alemtuzumab, cyclosporine or tacrolimus was administered
Study NCT03871920 — intervention group
Intervention type: OTHER
Intervention: physical therapy treatment
Description: any treatment chosen by treating physiotherapist
Study NCT00759447 — intervention group
Intervention type: DEVICE
Intervention: Genesis and Gemini
Description: 3 dimensional breast mammography system
Study NCT00759447 — intervention group
Intervention type: DEVICE
Intervention: Investigational 3D Mammography system
Description: 3 dimensional breast mammography system
Study NCT03861065 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tertiary Wound Closure
Description: The wound will be closed with what is considered tertiary wound closure. This means, rather than leaving the wound open, the wound will be partially closed after surgery, and then completely closed 4-7 days after surgery.
Study NCT03861065 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Historical Wound Closure
Description: Participants wounds are left partially open to heal.
Study NCT03749369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salvadora Persica Root
Description: Salvadora Persica Gel
Study NCT03749369 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing
Description: Thorough scaling and root planing (SRP) will be performed by a single clinician. The SRP procedure will be carried out in two sittings, comprising of ultrasonic scaling in the first, and manual instrumentation and root debridement in the second.
Study NCT03749369 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: Thorough scaling and root planing (SRP) will be performed by a single clinician. The SRP procedure will be carried out in two sittings, comprising of ultrasonic scaling in the first, and manual instrumentation and root debridement in the second.
Study NCT02581748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HLX02
Study NCT02218229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shock wave
Description: Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs). Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies or hypertrophic pseudoarthrosis
Study NCT02198833 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Urine Culture
Description: Obtain urine culture every third day
Study NCT02581748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX02
Study NCT02581748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Study NCT05070611 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPL-MGX
Description: One week after lesion incision, the E-Eye machine (E-SWIN company, France) IPL treatment was administered to the skin area below the lower eyelid.13 Before treatment, the eyes were protected with opaque goggles and ultrasound gel was applied on the patient's face from tragus to tragus including the nose to conduct the light.
Study NCT01813006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3
Study NCT01813006 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02808702 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Description: Twelve weekly sessions of individual cognitive-behavioral therapy
Study NCT02674477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Education System (TES)
Description: The TES program is made of modules about ways to prevent substance use, such as how to refuse drugs and alcohol, how to cope with thoughts about using, and how to make the best possible decisions for a person's mental health. Each module takes less than 30 minutes to complete. Modules may contain videos or other interactive media. At the end of each module, there are questions about the material.
Study NCT02674477 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual (TAU)
Description: Standard treatment comprises a psychiatrist-led interdisciplinary team as well as face-to-face group counseling for substance use and skills for improving general mental health. There will be no change to the routine care (treatment at usual \[TAU\]) provided to patients on the service.
Study NCT04879888 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide pulsed Dendritic cell
Description: Intradermal vaccination with peptide-pulsed autologous dendritic cells in 200 µL of patient's serum in six doses weekly after surgery.
Study NCT01415700 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulator
Description: The stimulator is surgically implanted
Study NCT01415700 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: feet orthosis
Description: feet orthosis specifically mold
Study NCT00189293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Imiquimod 5% cream three times per week for 4 weeks (1 sachet)~1 or 2 sachet(s)
Study NCT00189293 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: vehicle cream
Description: vehicle cream three times per week for 4 weeks (1 sachet)~1 or 2 sachet(s)
Study NCT01544127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI-SI+TAU
Description: MI-SI focuses on exploring and resolving ambivalence about living. It consists of 1 or 2 in-person MI-SI sessions (50 mins.) on an inpatient unit, plus a telephone follow-up MI-SI session (30-50 mins)
Study NCT01544127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI-SI-R+TAU
Description: MI-SI-R focuses on resolving ambivalence about living. It consists of 1 or 2 in-person MI-SI sessions (50 mins.) on an inpatient unit, plus a telephone follow-up MI-SI session (30-50 mins)
Study NCT01544127 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: TAU Alone
Description: Inpatient treatment includes medication management, case management, meals and a bed, milieu therapy consisting of creative and social activities, and a safety plan. Some families of veterans also received education to create a supportive home environment. As part of Veterans Health Administration (VHA) suicide prevention policy, the care of suicidal patients is also overseen by a local Suicide Prevention Coordinator and case managers.
Study NCT04088773 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood biomarkers
Description: biomarkers to distinguish fibrotic vs non-fibrotic CD lesions
Study NCT04088773 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: stool biomarkers
Description: fecal biomarkers of inflammation, mucosal inflammation
Study NCT04088773 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI imaging
Description: MRI imaging to detect bowel wall fibrosis and to detect inflamed, non-fibrotic from inflamed, fibrotic bowel
Study NCT00005006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parathyroid Hormone
Description: Alendronate 70mg/week; Teriparatide 20mcg/ day
Study NCT04598113 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical Traction Device
Description: While The patient is lie on the back his or her head is housed within the specific head portion of the device. The investigator inflate progressively the device using a valve and ensuring the patient's relaxation. The process of inflation is continued until the level of 12 Kg of pressure is reached. This maximum level of traction is maintained for 10 minutes then the process of deflation is started until the pressure decreased to 0 Kg. This maneuver is reproduced once again after 5 minutes of rest.~The balance assessment using the force plate-from is done just before the intervention and 5 minutes after its end.
Study NCT04598113 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cervical Traction Device
Description: While The patient is lie on the back his or her head is housed within the specific head portion of the device. The investigator inflate progressively the device using a valve and ensuring the patient's relaxation. The process of inflation is continued until the level of 12 Kg of pressure is reached. This maximum level of traction is maintained for 10 minutes then the process of deflation is started until the pressure decreased to 0 Kg. This maneuver is reproduced once again after 5 minutes of rest.~The balance assessment using the force plate-from is done just before the intervention and 5 minutes after its end.
Study NCT00992888 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prometheus Liver Dialysis system (Fresenius Medical Care)
Description: 6 hour dialysis for 3 consecutive days
Study NCT00005006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: Alendronate 70mg/week
Study NCT00005006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: Teriparatide 20mcg/day
Study NCT02932878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSXS topical
Description: topical treatment
Study NCT02262377 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative Medicine Group Visits
Description: Patients with chronic pain and depression attend group medical visits and use website and virtual patient advocate as part of the curriculum.
Study NCT03292653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Pharmaceutical form: Tablet; Route of administration: Oral
Study NCT02198833 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Urine Culture
Description: Obtain urine culture every third day
Study NCT01975324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalfampridine
Description: dalfampridine 10 mgs or placebo twice a day for two weeks, wash out period of two weeks, dalfampridine 10mgs or placebo twice a day for two weeks
Study NCT01975324 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo (sugar pill) twice a day for two weeks
Study NCT02365142 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 100 million Bone marrow mesenchimal stem cells
Description: 100 million Bone marrow mesenchimal stem cells with PRGF
Study NCT02365142 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich plasma (PRGF)
Description: 3 injections of PRGF
Study NCT00837733 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy
Description: Endometrial biopsy was done at luteal phase on the day 21-26 of spontaneous menstrual cycles, when GnRH agonist uses begun. Endometrial samples were taken by a biopsy catheter
Study NCT00837733 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial Biopsy
Description: Biopsy catheter
Study NCT02198833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley Catheter Tip Culture
Description: Catheter Tip Roll Plate Culture
Study NCT02198833 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley Catheter Tip Culture
Description: Catheter Tip Roll Plate Culture
Study NCT02198833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scanning Electron Microscopy
Description: Houston Site Only
Study NCT02198833 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Scanning Electron Microscopy
Description: Houston Site Only
Study NCT02198833 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Device Specific Adverse Event Assessment
Description: Assessment will be made of catheter patency and/or trauma related to catheter placement
Study NCT02198833 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Device Specific Adverse Event Assessment
Description: Assessment will be made of catheter patency and/or trauma related to catheter placement
Study NCT02198833 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Foley Catheter Insertion
Description: Insert Foley catheter for 15 day duration
Study NCT02198833 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Foley Catheter Insertion
Description: Insert Foley catheter for 15 day duration
Study NCT01984515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral Management System
Description: Referral Management System (RMS) will address patient-level barriers with the delivery of a 1-session cognitive behavioral therapy (CBT) intervention to identify and change treatment seeking beliefs that serve as an barrier to treatment engagement, including specific negative beliefs about EBP (e.g., talking about past trauma will be too difficult for me). RMS will address system-level barriers by tracking the progress of RMS referrals and contacting Veterans who have not followed thought on their chosen referral options. Primary Care staff will also be trained with simple scripts on how to address PTSD symptoms and make appropriate referrals based on VA/DoD Clinical Practice Guidelines for PTSD.
Study NCT02324166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: cephalosporin antibiotic
Study NCT02324166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: local anesthetic
Study NCT01756456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNGF 10 μg/ml
Description: rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)
Study NCT03292653 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Tablet; Route of administration: Oral
Study NCT03292653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: Tablet; Route of administration: Oral
Study NCT04038710 — intervention group
Intervention type: DRUG
Intervention: Triple combination therapy
Description: Triple combination is compromised of the drugs ivacaftor, tezacaftor and Vertex's next generation modulator.
Study NCT03478436 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Doxycycline
Description: Doxycycline 40 mg capsules
Study NCT00366093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: eszopiclone 3 mg